Anacor Pharmaceuticals, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 17,228 10,740 20,306 27,824
Cost of Revenue - - - -
Gross Profit 17,228 10,740 20,306 27,824
Operating Expenses
Research and Development 46,561 52,318 56,097 29,866
Sales, General and Admin. 20,650 11,614 10,552 7,452
Non-Recurring Items - - - -
Other - - - -
Operating Income 92,517 (53,192) (46,343) (9,494)
Income From Continuing Operations
Add'l Income/Expense Items 140,505 19 (205) 1,441
Earnings Before Interest and Tax 90,522 (53,173) (46,548) (8,053)
Interest Expense 4,051 2,914 1,396 2,005
Earnings Before Tax 86,471 (56,087) (47,944) (10,058)
Income Tax 1,706 - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations 83,384 (56,087) (48,257) (10,058)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income 84,765 (56,087) (47,944) (10,058)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders 84,765 (56,087) (47,944) (10,058)